INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY

Available online at www.ijrpc.com

Research Article

SYNTHESIS, CHARACTERISATION AND ANTICONVULSANT ACTIVITY OF 1-(ARYL)-3-(DIPHENYLMETHYL) UREA DERIVATIVES

Dandagvhal Kamlesh Ramesh, Shirsath Pratibha Gangadhar and SA. Katti

Department of Pharmaceutical Chemistry, MGV's pharmacy college, Panchavti, Nashik, Maharashtra, India.

ABSTRACT

Some 1-(Aryl)-3-(diphenylmethyl)urea derivatives were synthesized using microwave irradiations. The structures of title compounds were confirmed by ¹HNMR, MS (EI), FT-IR. All synthesized compounds were evaluated for anticonvulsant activity by PTZ induced convulsions in mice and 1-(4-methoxyphenyl)-3-(diphenylmethyl)urea and 1-(4-chlorophenyl)-3-(diphenylmethyl)urea were found possess potent anticonvulsant activity. During these synthesis we have also noted that when urea is replaced by 1N-phenylurea or substituted 1N-phenylurea in a reaction with Benzil, it do not follow pinacol-pinacolone rearrangement to form hydanoin derivaives but forms 1-(Aryl)-3-(diphenylmethyl) urea derivatives.

Keywords: urea, microwave, hydantoin, PTZ, anticonvulsant.


INTRODUCTION

The urea derivatives such as N-nitrosoureas, benzoylureas, thioureas, and diarylsulphonylureas represent one of the most useful classes of anticancer agents, with a wide range of activities against leukemias and solid tumors.1 Many urea-derived herbicides possess cytokinin-like activity (Krikorian, 1995). 1-benzhydryl-3-phenylureas, as cannabinoid receptor 1 are reported inverse agonist which lead to reduction in appetite and can be used as anti obesity agent.³ It has been reported that various urea derivatives has antimicrobial,¹ hypoglycemic,² anticonvulsant activity. Ureas and monoacylurea derivatives also posses anticonvulsant activity (ex. Phenacemide).4 work, 1-(Aryl)-3present In (diphenylmethyl)urea derivatives were synthesised using various 1N-arylurea and benzil in presence of 10% KOH and DMSO under microwave irradiation. Synthesised compounds were evaluated for anticonvulsant

activity by PTZ induced convulsion in animal model.

MATERIAL AND METHODS

All the chemicals, solvents used for this work were obtained from S D fine-chem Ltd. (SDFCL), Mumbai. Reactions were carried on 'Catalvst systems Scientific microwave Melting points of synthesised System'. compounds were determined in open capillary tube using digital melting point apparatus VMP-D expressed in ⁰C and were uncorrected. Silica gel chromatographic plates were used for TLC. IR spectra were recorded in KBr on FT-IR8400S SHIMADZU spectrometer. Mass spectra were recorded on GCMS QP2010 SHIMATZU instrument. ¹HNMR spectra were recorded on Mercury Plus 300 MHz model with TMS as an internal standard. Chemical shifts (δ) were expressed in parts per million (δ ppm).



Synthesis of phenylurea derivatives

In a 250ml Beaker, aniline (0.1mol) was dissovled in 10 ml of glacial acetic acid, and diluted to 100ml with water. Solution of sodium cyanate (0.1mol) in 50ml of warm water was added to above mixture. It was allow standing for 30min. and then product was filtered.⁵ Similarly some phenylurea derivatives listed in table no. 1 were prepared.

Synthesis of 1-(Aryl)-3-(diphenylmethyl)urea derivatives

Mixture of Benzil (7.14 mmol) and substituted phenylurea (14.3 mmol) was irradiated with microwave (350W for 20 min.) in presence of 10% aqueous KOH using DMSO as solvent and progress of reaction was monitored by TLC. On completion of the reaction, the mixture was cooled and poured into ice-cold water. Resulting solid was filtered, washed with water and recrystallised from ethanol. Similarly 1-(Aryl)-3-(diphenylmethyl)urea derivatives listed in table no.2 were prepared.

1-(diphenylmethyl)-3-phenylurea (PBU)

M.P. 202-204^oC, MS (EI): 302[M]⁺. ¹HNMR (300MHz):6.2δppm(s,1H), 6.4δppm(s,1H) 7.3-7.6δppm (m,15H), 8.5δppm(s,1H). IR (KBr): 3348.54cm⁻¹ (N-H stretch), 3039.91cm⁻¹ (C-H aromatic stretch), 2908.75cm⁻¹ (C-H stretch, Aliphatic) 1648.00 (C=O stretch), 1597.11cm⁻¹ (C=C stretch, aromatic), 1242.20cm⁻¹ (C-N stretch).

1-(4-methoxyphenyl)-3-(diphenylmethyl)urea (PABU)

M.P. 216-217°C, MS (EI): 332M]⁺. ¹HNMR (300MHz): 3.85ppm (s,3H), 6.25ppm (s, 1H), 6.05ppm (s, 1H), 6.9-7.35ppm (m, 14H), 8.35ppm(s, 1H). IR (KBr): 3319.60cm⁻¹ (N-H stretch), 3041.84cm⁻¹ (C-H, aromatic stretch), 2990.53cm⁻¹ (C-H stretch, Aliphatic), 1681.98cm⁻¹ (C=O stretch), 1620.26cm⁻¹ (C=C stretch, aromatic), 1249.51cm⁻¹ (C-N stretch), 1327.07cm⁻¹ (C-O stretch).

1-(4-chlorophenyl)-3-(diphenylmethyl)urea (PCBU)

M.P. $212-213^{\circ}$ C. MS (EI): $336[M]^{+}$. ¹HNMR (300MHz): 6.0δ ppm (s,1H), 6.3δ ppm (s,1H), 7.3-7.7\deltappm (m,14H), 8.2δ ppm(s,1H). IR (KBr): 3302.24cm⁻¹ (N-H stretch), 3055.35cm⁻¹ (C-H aromatic stretch), 2916.47cm-1 (C-H stretch, aliphatic), 1743.71cm⁻¹ (C=O stretch), 1489.10cm⁻¹ (C=C aromatic stretch), 1172.76cm⁻¹(C-N stretch), 671cm⁻¹(C-CI stretch).

1-(4-methylphenyl)-3-(diphenylmethyl)urea (PMBU)

M.P. 206-207С, MS (EI): 316[M]⁺. ¹HNMR (300MHz): 2.34δррт (s,3H), 6.1δррт (s, 1H), 6.3δррт (s,1H), 7.3-7.5δррт (m,14H), 8.27δррт (s,1H). IR (KBr): 3340.82cm⁻¹ (N-H stretch), 3039.91cm⁻¹ (C-H aromatic stretch), 2990.53cm⁻¹ (C-H stretch, Aliphatic), 1647.00cm⁻¹ (C=O stretch), 1597.11cm⁻¹ (C=C stretch, aromatic), 1219.05cm⁻¹(C-N stretch).

1-(4-bromophenyl)-3-(diphenylmethyl)urea (PBBU)

M.P. 223-224°C, MS (EI): 380[M]⁺. 382[M+1]⁺. ¹HNMR (300MHz): 6.15ppm (s.1H), 6.25ppm (s,1H), 7.2-7.7δppm (m,14H), 8.2δppm (s,1H). 3354.48cm⁻¹ IR (KBr): (N-H stretch). 3178.79cm⁻¹ aromatic (C-H stretch), 2901.04cm⁻¹ (C-H stretch, Aliphatic), 1635.69cm⁻¹ (C=O stretch), 1597.11cm⁻¹ (C=C aromatic stretch), 1219.05cm (C-N stretch), 694cm⁻¹(C-Br stretch).

1-(4-flurophenyl)-3-(diphenylmethyl)urea (PFBU)

M.P. 223-224^oC, MS (EI): $320[M]^+$. IR (KBr): 3316.41 cm^{-1} (N-H stretch), 3162.81 cm^{-1} (C-H aromatic stretch), 2943.53 \text{ cm}^{-1} (C-H stretch, Aliphatic), 1659.49 cm^{-1} (C=O stretch), 1593.19 cm^{-1} (C=C aromatic stretch), 1226.57 cm^{-1} (C-N stretch), 682 cm^{-1} (C-F stretch).

Anticonvulsant activity

The Institutional Animal Ethics Committee approved the protocol adopted for the experimentation of animals. Male Swiss Albino mice, weighing 18-25 gm were procured from Bharat Serums and Vaccines Ltd., Thane, Mumbai, India. All the animals were acclimatized for a week before use. All newly synthesized compounds were tested *in vitro* in order to evaluate their anticonvulsant activity at fixed dose 20mg/kg. Mice were divided into 9 groups containing five animals each.

PTZ induced convulsions animal model was used to evaluate anticonvulsant activity:

1-(Aryl)-3-(diphenylmethyl)urea The derivatives (20mg/kg p.o.) were administered in test groups. PTZ (60mg/kg s.c.) was administered in control group. Diazepam (10mg/kg i.p.) was administered to in standard 60 min (oral dose). group. After mg/kg s.c.) pentylenetetrazole (60 was administered and placed individual mice immediately in the centre of the flaxy glass chamber and observed for one hour. The latency period for each phase has recorded.⁶ Data is represented in table no 3 and figure no.1

RESULT AND DISCUSSION

Substituted 1N-phenylurea were synthesised by using respective aniline with sodium cyanate and data is listed in table no 1. Using substituted 1N-phenylurea different 1-(Aryl)-3-(diphenylmethyl)urea derivatives were synthesised under microwave irradiation (350W for 30min.). The physicochemical data of synthesised compounds is listed in table no.2. Purity of all synthesised compounds was confirmed by melting point and TLC. All synthesised compounds were analysed by FT-IR, MS (EI), ¹HNMR. Anticonvulsant activity was evaluated using PTZ induced convulsion in mice using Diazepam as standard. Results obtained are listed in table no.3, figure no.1. In this all synthesised derivatives of 1-(Aryl)-3-(diphenylmethyl)urea possess anticonvulsant activity. Compounds PABU, PCBU are more potent anticonvulsant activity than PBU, PMBU and PBBU. During these synthesis we have also noted that when urea is replaced by 1N-phenylurea or substitued 1N-phenylurea in a reaction with Benzil, it do not follow pinacolpinacolone rearrangement to form hydanoin derivaives but forms 1-(Aryl)-3-(diphenylmethyl)urea derivatives.

CONCLUSION

Simple convenient method for synthesis of 1-(Aryl)-3-(diphenylmethyl)urea was developed microwave svstem. Synthesised on compounds were confirmed by ¹HNMR, MS (EI), FT-IR. All synthesised derivatives of 1-(Aryl)-3-(diphenylmethyl)urea shows significant anticonvulsant activity. Electron donating substitutions on para position of 3phenyl ring shows increase, while halogens such as fluorine, Bromine when substitued at para position of 3-phenyl ring shows decrease in anticonvulsant activity. More extensive study is needed to confirm the mode of action and to optimise the effectiveness of these compounds.

ACKNOWLEDGEMENT


The authors are thankful to department of Pharmaceutical Chemistry, MGV's pharmacy college, Panchavati, Nashik and University of Pune for providing the facilities for experiments and instrumental analysis of synthesised derivatives.

S. No.	compound	Molecular formula	Molecular weight	% yield	Melting point (⁰C)	Rf value
1	1-phenylurea	C ₇ H ₈ N ₂ O	136	97	148-150	0.56
2	1-(4-methoxy)phenylurea	C ₈ H ₁₀ N ₂ O ₂	166	93	165-167	0.60
3	1-(4-chloro)phenylurea	C ₇ H ₇ CIN ₂ O	170	96	140-142	0.48
4	1-(4-methyl)phenylurea	C ₈ H ₁₀ N ₂ O	150	98	183-185	0.52
5	1-(4-bromo)phenylurea	C ₇ H ₇ BrN ₂ O	214	92	158-160	0.63
6	1-(4-fluro)phenylurea	C ₇ H ₇ FN ₂ O	154	88	194-196	0.65

Table 1: physicochemical data of substituted 1-(aryl)urea

Mobile phase- ethyl acetate: n-Hexane (7:3)

Table 2: physicochemical data of 1-(Aryl)-3-(diphenylmethyl)urea derivatives



S. No.	Treatment groups	Straub Tail (sec)	Jerky M. (sec)	Clonic. C (sec)	Death (sec)
1	Normal	0	0	0	0
2	Control	45.6± 1.85	54± 2.08	73.33± 4.37	97.67± 3.84
3	DZP	0	0	0	0
4	PBU	88.67± 8.19	94.67± 4.66	140.7± 3.75	207.3± 103.0
5	PFBU	138.7± 8.11	124.7± 9.52	229.3± 6.53*	243.3± 122.0
6	PCBU	215.7± 18.75	933.7± 12.71*	881± 50.86*	0
7	PABU	299± 19.86	1052± 52.63*	994.7± 8.56*	0
8	PMBU	102.3± 12.4	249.7± 2.13	317.3± 17.34*	0
9	PBBU	120± 1.99	232.3± 3.71	551± 5.85*	170.7± 170.0

Mobile phase- ethyl acetate: n-Hexane (7:3)

Table 3: Anticonvulsant activity of 1-(Aryl)-3-(diphenylmethyl)urea	
derivatives by PTZ induced convulsions test in mice	

S. No.	X/R	Molecular formula	Molecular weight	% Yield	Melting point (⁰ C)	Rf value
1	Н	C ₂₀ H ₁₈ N ₂ O	302	88	202-204	0.52
2	P-OCH ₃	$C_{21}H_{20}N_2O_2$	332	91	216-217	0.53
3	P-CI	C ₂₀ H ₁₇ CIN ₂ O	336	84	212-214	0.50
4	P-methyl	$C_{21}H_{20}N_2O$	316	97	206-207	0.55
5	P-Br	$C_{20}H_{17}BrN_2O$	380	98	223-224	0.41
6	P-F	$C_{20}H_{17}FN_2O$	320	92	176-178	0.51

All values are expressed as mean ± SEM, n=5, *p<0.05 compared with control.

Statistical analysis was performed with One-way ANOVA followed by Dunnett's test. p<0.05 was considered as statistically significant.




Fig. 1: anticonvulsant activity of 1-(Aryl)-3-(diphenylmethyl)urea derivatives for anticonvulsant activity by PTZ induced convulsions test in mice

REFERENCES

- Mulathi S. Potentional application of urea derivative. Journal of bioscience. 2006;31:599-605.
- 2. Giulio G Muccili and Didier M Lambert. organic latters. 2003;5(20):3599-3602.
- 3. Giulio G Muccili and Didier M Lambert. Journal of medicinal chemistry, 2005, 48, 7486-7490.
- 4. Thomas LL, Devid LW and Wolters Kluwrs. Principles of Medicinal chemistry. 2006;sixth edition, 521-545.
- 5. Furniss BS, Hannaford AJ, Smith PWG and Tatchell AR. Vogel's "Textbook of practical Organic Chemistry." Singapore: Pearson Education, 2004, fifth edition 1269, 708.
- 6. Vogel GH. Drug Discovery and Evaluation. published by spinger publication, 2004, second edition, 422-423.
- Dunnavant WR. Molecular rearrangement- The base catalyzed condensation of benzil with urea", Journal of American Chemical Society. 1956;78(12):2740–2743.
- 8. Ghosh SK. Advanced general organic chemistry. A modern approach, part-1, new central book agency pvt ltd. 2009, third edition, 701-711.

- 9. Thripathi KD. Essentials of Medical Pharmacology. Jaypee brothers medical publisher, 2009, sixth edition, 401-414.
- 10. Kulkarni SK. Hand Book of Experimental Pharmacology", vallabh prakashan, 2010, third edition, 133-135.